Cargando…

Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boquoi, A., Banahan, S. M., Mohring, A., Savickaite, I., Strapatsas, J., Hildebrandt, B., Kobbe, G., Gattermann, N., Haas, R., Schroeder, T., Germing, U., Fenk, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993729/ https://www.ncbi.nlm.nih.gov/pubmed/35262868 http://dx.doi.org/10.1007/s00277-022-04775-1

Ejemplares similares

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
por: Boquoi, Amelie, et al.
Publicado: (2022)

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
por: Platte, Victoria, et al.
Publicado: (2022)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
por: Boquoi, Amelie, et al.
Publicado: (2023)

18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?
por: Zukovs, Romans, et al.
Publicado: (2022)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
por: Rautenberg, Christina, et al.
Publicado: (2019)

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
por: Kasprzak, A., et al.
Publicado: (2020)

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
por: Kasprzak, Annika, et al.
Publicado: (2021)

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma
por: Metselaar, Josbert, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience
por: Jäger, Paul, et al.
Publicado: (2023)

A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): A case report
por: Schroeder, Thomas, et al.
Publicado: (2008)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Mesenchymal stromal cells in myeloid malignancies
por: Schroeder, Thomas, et al.
Publicado: (2016)

Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
por: Sternke-Hoffmann, Rebecca, et al.
Publicado: (2023)

Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients
por: Strapatsas, Judith, et al.
Publicado: (2021)

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
por: Kuendgen, Andrea, et al.
Publicado: (2018)

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
por: Silzle, Tobias, et al.
Publicado: (2019)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
por: Kasprzak, A., et al.
Publicado: (2022)

Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
por: Geyh, Stefanie, et al.
Publicado: (2018)

Impaired formation of neutrophil extracellular traps in patients with MDS
por: Brings, Carolin, et al.
Publicado: (2022)

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2021)

Biochemical and biophysical characterisation of immunoglobulin free light chains derived from an initially unbiased population of patients with light chain disease
por: Sternke-Hoffmann, Rebecca, et al.
Publicado: (2020)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US
por: Bhattacharya, Kaustuv, et al.
Publicado: (2021)

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score
por: Silzle, Tobias, et al.
Publicado: (2023)

Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience
por: Bouchla, Anthi, et al.
Publicado: (2019)

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
por: Rautenberg, Christina, et al.
Publicado: (2019)

EAHP 2020 workshop proceedings, pediatric myeloid neoplasms
por: Leguit, R. J., et al.
Publicado: (2022)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
por: Jain, Salvia, et al.
Publicado: (2011)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Co-occurrence of myeloid neoplasm and plasma cell neoplasm
por: Jum’ah, Husam, et al.
Publicado: (2022)

A case of synchronous multiple myeloma and chronic myeloid leukemia
por: Lee, Ji-Young, et al.
Publicado: (2017)

Extracellular Vesicles in Myeloid Neoplasms
por: Karantanou, Christina, et al.
Publicado: (2022)

Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution
por: Matuschek, Christiane, et al.
Publicado: (2015)

The simultaneous occurrence of multiple myeloma and JAK2 positive myeloproliferative neoplasms - Report on two cases
por: Badelita, S, et al.
Publicado: (2015)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Clonal relationship between langerhans cell histiocytosis and myeloid sarcoma
por: Schmitt-Graeff, A H, et al.
Publicado: (2012)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f928vfe9guh7u0g6i9su911osb